Clinical studies have shown that a significant increase in levels of TGFβ1 in the serum of patients with breast cancer, lung cancer, hepatoma, prostate cancer, and stage I and stage II endometrial carcinoma [11,12]. The gene discussed is TGFB1; the disease is endometrial carcinoma.